Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

948 recalls · Class II, newest first

Class II · Moderate risk

SUCCINYLcholine Chloride 200 mg/10mL

CGMP Violations- that spaces adjacent to the production area may have been compromised at the time of production.

Terminated cGMP deviation New England Life Care, Inc. dba Advanced Compounding Solutions D-0926-2023
Class II · Moderate risk

Sunitinib Malate Capsules

Failed Moisture Limits: Water (moisture) content above the approved product specifications.

Terminated Failed specification Teva Pharmaceuticals USA Inc NDC 0093-8199-28 D-0913-2023
Class II · Moderate risk

Tizanidine Tablets

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Terminated Dissolution failure Amerisource Health Services LLC NDC 68084-645-01 D-0892-2023
Class II · Moderate risk

Tizanidine Tablets USP

Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Ongoing Dissolution failure Dr Reddy's Laboratories Limited NDC 55111-180-10 D-0923-2023
Class II · Moderate risk

Dry Eye Relief Lubricant Eye Drops

CGMP Deviations: good manufacturing deficiencies related to a lack of documentation of the fill line.

Ongoing cGMP deviation K.C. Pharmaceuticals, Inc NDC 49035-280-02 D-0898-2023
Class II · Moderate risk

Original Eye Drops

CGMP Deviations: good manufacturing deficiencies related to a lack of documentation of the fill line.

Ongoing cGMP deviation K.C. Pharmaceuticals, Inc NDC 49348-037-29 D-0897-2023
Class II · Moderate risk

Endometrin

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023

Recalls by year